Ono Pharmaceutical Co Stock Today
| OPHLF Stock | USD 11.19 0.47 4.38% |
PerformanceOK
| Odds Of DistressLow
|
Ono Pharmaceutical is trading at 11.19 as of the 20th of March 2025. This is a 4.38 percent increase since the beginning of the trading day. The stock's lowest day price was 11.19. Ono Pharmaceutical has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 488.31 M outstanding shares. More on Ono Pharmaceutical Co
Moving together with Ono Pink Sheet
Moving against Ono Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ono Pink Sheet Highlights
| CEO | Gyo Sagara |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Ono Pharmaceutical Co [OPHLF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ono Pharmaceutical's market, we take the total number of its shares issued and multiply it by Ono Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ono Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 488.31 M outstanding shares.
Ono Pharmaceutical Co has accumulated about 136.18 B in cash with 61.83 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 278.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ono Pharmaceutical Probability Of Bankruptcy
Ownership AllocationOno Pharmaceutical owns a total of 488.31 Million outstanding shares. 30% of Ono Pharmaceutical Co outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ono Ownership Details
Ono Pharmaceutical Risk Profiles
| Mean Deviation | 4.88 | |||
| Standard Deviation | 7.07 | |||
| Variance | 49.97 | |||
| Risk Adjusted Performance | 0.0039 |
Ono Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ono Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Ono Pharmaceutical Corporate Directors
| Hiromu Habashita | Executive Officer, Chief Director of Research | Profile | |
| Katsuji Teranishi | Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | Profile | |
| Toshihiro Tsujinaka | Executive Officer, Senior Director of Oncology in Main Sales Unit | Profile | |
| Hiroshi Ichikawa | Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | Profile |
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.